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Impact of Calciﬁed Plaque on Stent Strut Distribution of Bioresorbable Vascular
Scaffolds Versus Metallic Everolimus-eluting Stents: An Optical Coherence
Tomography Analysis
Katsumasa Sato1, Azeem Latib1, Vasileios F. Panoulas1, Hiroyoshi Kawamoto1,
Tadashi Miyazaki1, Toru Naganuma1, Antonio Colombo1
1EMO GVM Centro Cuore Columbus, Milan, Italy
Background: Non-uniform strut distribution (NSD) is an important factor predis-
posing to intimal hyperplasia through decreased local drug delivery and increased
scaffold recoil after BVS implantation. The aim of this study was to evaluate, using
optical coherence tomography (OCT), the impact of underlying plaque morphology on
strut distribution of bioresorbable vascular scaffolds (BVS 1.1) versus metallic ever-
olimus eluting stents (EES).
Methods: Among 39 patients who underwent elective percutaneous coronary inter-
vention (PCI) (n¼20 in BVS group, n¼19 in EES group), a total of 1200 post-PCI
OCT frames (BVS: 590 frames; EES: 610 frames) were analyzed. NSD was deﬁned as
a frame with maximum inter-strut angle i 120.
Results: The percentage of frames with NSD was signiﬁcantly higher in the BVS
group (26.1% [154/590] vs. 19.0% [116/ 610], p¼0.003). In the EES group the cal-
cium arc in frames with NSD was not signiﬁcantly different compared to that in
frames with uniform strut distribution (USD) (34.644.4 vs. 35.647.1, p¼0.83).
However, in the BVS group the arc of calcium was signiﬁcantly greater in frames with
NSD as compared to those with USD (85.262.6 vs. 21.041.7, p< 0.0001). In
multivariable analysis, after adjustment for post-dilatation balloon size and maximum
inﬂation pressure, a calcium arc >75 was identiﬁed as an independent predictor of
NSD after BVS implantation (odds ratio: 12.1, 95% conﬁdence interval: 7.9-18.8, p<
0.001).
Conclusions: The presence of calciﬁed plaque behind BVS struts appears to be an
independent predictor for NSD. For calciﬁed lesions, meticulous lesion preparation,
including use of dedicated devices, may help prevent NSD after BVS stent
implantation.
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Background: There are limited data regarding clinical outcomes of patients with
complex lesions treated with bioresorbable vascular scaffolds (BVS) compared to new
generation drug eluting stents (DES).
Methods: We analyzed 1-year clinical outcome data of 432 consecutive patients
treated with either new-generation DES or BVS between May 2008 and May 2014.
Propensity score (PS) matching was applied prior to comparisons between the two
groups. Primary outcome was major adverse cardiac events (MACE) which was
deﬁned as all-cause death, follow-up myocardial infarction (MI) and target-vessel
revascularization (TVR).
Results: A total of 432 patients were included in this study. After PS matching,
96 patients treated with BVS (BVS group) and 96 patients treated with DES
(DES group) were selected. Lesion characteristics were similar between two
groups. Over 80% of lesions in both cohorts were ACC/AHA lesion classiﬁcation
type B2 and C (83.3% in BVS vs. 85.2% in DES, p¼0.68). Pre and post-dila-
tation in BVS group were performed more frequently compared to that in DES
group (100% vs. 72.1%, p< 0.01; 100% vs. 86.4%, p< 0.01), and maximum
inﬂation pressure after stenting in BVS group was higher than that in DES group
(21.15.1 atm vs. 18.45.1 atm, p< 0.01). There was no signiﬁcant difference in
the 1-year cumulative MACE incidence between the BVS and the DES group
(10.8% vs. 12.7%, p¼0.33). Similarly there was no signiﬁcant differences in the
composite endpoint of all-cause death and MI (3.6% vs. 4.5%, p¼0.30), TVR
(10.8% vs. 9.6%, p¼0.80) or target lesion revascularization (9.2% vs. 5.6%,
p¼0.51). There was 1 episode of deﬁnite stent thrombosis in BVS group and 1 in
EES group.
Conclusions: In the present all-comers cohort with a high proportion of complex
lesions, the 1-year MACE in the BVS group was similar to that of patients treated
with new generation DES. In the BVS group, however, meticulous lesion prepa-
ration including dedicated balloons may be needed to achieve similar clinical
outcomes.B184 JACC Vol 64/11/Suppl B j September 13–1TCT-632
Diabetes and Atherosclerosis Do Not Affect Early Degradation of Bioresorbable
Vascular Scaffolds
Mie Kurata1, Nienke S. van Ditzhuijzen1, Oana Sorop1, Richard W. van Duin1,
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Background: While everolimus-eluting bioresorbable vascular scaffolds (BVS) were
studied in healthy swine, effects of inﬂammation and atherosclerosis on degradation of
BVS and vascular behaviour remain to be determined.
Methods: Of 15 farm-bred swine, 8 received streptozotocin to induce diabetes mel-
litus (DM), then a high cholesterol diet was given to all 15 swine. Nine months later,
32 coronary Absorb BVS (Abbott Vascular, Santa Clara, CA) were implanted under
angiographic guidance. Histology, serology and polymer degradation analysis was
performed. Results of degradation were compared to controls from normal, non-
atherosclerotic swine (n ¼ 6/ time point).
Results: Degradation was similar in diseased and normal healthy swine and was
determined only by implanted duration. It was not affected by DM, lipid accumulation
in the neointima, or inﬂammation (Fig). Struts were completely covered at both 3 and
6 months follow-up, irrespective of DM and atherosclerosis. Likewise, DM did not
affect histological scores. Importantly, all disease groups showed marked neointimal
atherosclerosis, with focal lipid accumulation, irregular collagen distribution and
neointimal calciﬁcations. The latter was observed in various patterns, particularly
towards the lumen.Conclusions: In swine coronary arteries, DM, atherosclerosis and inﬂammation do
not affect BVS degradation or the vascular response to BVS. Both in DM and non-
DM, the neointima was equally associated with calciﬁcation, lipid accumulation and
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Background: Compared to drug eluting stents, for bioresorbable vascular scaffolds
(BVS, Abbott Vascular Inc., Santa Clara, CA) sizing may be more important in terms
of malapposition and fracture because of smaller expansion limits. The registry aims7, 2014 j TCT Abstracts/Stents - Drug-eluting: Bioresorbable Scaffolds
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMto investigate the safety and efﬁcacy of the BVS in a real world setting, waiving
obligatory IVUS or OCT guidance.
Methods: Consecutive patients with ischemic heart disease and de novo native
coronary artery lesions were enrolled at 6 German centers in the prospective,
observational registry. During the ﬁrst 6 months of enrollment, only 3.0 x 18 mm
BVS were available. From then onwards, 2.5 mm, 3.0 mm, and 3.5 mm BVS of
different length were also available. BVS sizing was based on visual estimate of
the lesions.
Results: A total of 183 patients were treated with BVS. A complex ACC/AHA
lesion morphology of B2 or C was seen in 128 (64.7%) lesions. Compared to
QCA, visual estimate overrated the baseline reference vessel diameter (RVD) by
0.5  0.5 mm and the diameter stenosis (DS) by 13.2  16.5 %. Nevertheless,
the ﬁnal minimal lumen diameter (MLD) closely matched the baseline RVD.
Diameter stenosis was 64.6  15.1% at baseline and improved to a residual DS
of 16.1  7.7%. Acute gain of MLD was 1.54  0.51 mm. A BVS-RVD
mismatch resulted in an optimal MLD but an overexpanded RVD in case of 3.0
BVS for < 2.5 mm vessels, whereas in 3.3 mm vessels ﬁnal MLD fell below the
RVD. Final RVD exceeded the BVS expansion limit in 20 (10.1%) lesions. No
periprocedural dissection was reported from the core laboratory. At 12 months, 1
(0.5%) death due to gastrointestinal bleeding under dual antiplatelet therapy and
3 (1.6%) myocardial infarctions, caused by non-target vessel failure, had
occurred. Target lesion revascularization had to be carried out in 5 patients
(2.8%).
Conclusions: Visual overestimation of baseline RVD resulted in an optimal ﬁnal
MLD. BVS-RVD mismatch may led to an inappropriate RVD or MLD. Acute
gain and frequency of MACE were in agreement with previous BVS and DES
studies.
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ACUTE AND MID-TERM CLINICAL OUTCOMES OF THE EVEROLIMUS-
ELUTING BIORESORBABLE VASCULAR SCAFFOLDS IN AN ALL-
COMER COHORT
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Background: Bioresorbable vascular scaffold (BVS) heralded as the fourth revolution
in interventional cardiology. Previous studies demonstrated the safety and efﬁcacy of
bioresorbable everolimus-eluting scaffolds in selected group of patients. However,
limited data are available on the clinical use and outcomes of BVS in the real life
setting.
Methods: Between November 2012 and April 2014, 89 consecutive patients were
treated with BVS and enrolled in a prospective single center registry. The indication of
BVS was left to the discretion of the operator.
Results: Mean age was 5911 years old and males in 69%. They had hyper-
tension in 56%, dyslipidemia in 52%, and diabetes in 29%, smokers in 48% and
known coronary artery disease in 20%. Clinical presentation was acute coronary
syndrome in 70 % of patients. Patients had a single vessel disease in 66% and the
left ventricular ejection fraction (LVEF) was 588%. One hundred sixteen le-
sions were treated (30% were type A, 62% type B and 8% type C). Average used
BVS/patient was 1.290.59. Mean BVS diameter and length were 3.10.35mm
and 225.25mm respectively. Procedural success and device success was
100%.The median follow-up was 199 days [29-365]. The in-hospital MACE rate
was low (1%; 1 case of acute deﬁnite BVS thrombosis). The cumulative mid term
MACE rate was 5 % (all cause mortality was 1% (probable BVS thrombosis); MI
1% (deﬁnite subacute BVS thrombosis) and 3% TLR (3 cases of in-BVS
restenosis).
Conclusions: In this all-comer cohort, BVS was mainly reserved to non-complex
cases and had a high acute procedural success with good mid term clinical outcomes.
Ongoing studies with long-term follow-up will conﬁrm the safety and efﬁcacy of BVS
in the treatment of more challenging cases.
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Background: The effect of mandatory non-compliant balloon(NCB) post-dila-
tion on bioresorbable vascular scaffolds(BVS) is not known. We sought toJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Steassess the impact of NCB post-dilation on optimizing BVS by using Optical
coherence tomography(OCT). We hypothesized that systematic post-dilation
to high pressures would signiﬁcantly improve expansion and reduce
malapposition.
Methods: In this ethics approved study we enrolled 18 patients. Per protocol,
mandatory pre-dilation was followed by intracoronary nitroglycerin and initial
OCT assessment. BVS was deployed at 14 atm for 30seconds and NCB post-
dilation performed at 16 atm for a minimum of 30seconds. OCT was repeated
after BVS deployment and after NCB post-dilation. All OCT images were
analyzed ofﬂine. Pre and post NCB post-dilation, the scaffold was analyzed for
minimum and mean diameters, and minimum scaffold cross-sectional area.
Optimal expansion of BVS was deﬁned as minimum scaffold area of 80% of
reference vessel area. The length of the scaffold was also assessed for clinically
relevant incomplete scaffold apposition (ISA) deﬁned as incomplete contact of
BVS struts with vessel wall for a distance of greater than the strut thickness of
0.15mm, over at least 25% of the scaffold circumference, and over a scaffold
length of at least 1mm.
Results: 22 lesions in 18 patients were analyzed. Mean patient age was 57.5yrs and
83% were male. The indication was stable angina in 83% cases. Using OCT, the
reference vessel diameter at baseline was 2.95mm. The mean BVS diameter used was
2.9mm and the mean diameter of NCB used was 3.5mm. After NCB post-dilation, the
minimum scaffold diameter increased by a mean of 0.19mm, the mean scaffold
diameter increased by a mean of 0.20mm and optimal expansion increased from 59%
to 86.4% of cases (p< 0.0001). After NCB use, clinically relevant ISA decreased from
5 to 3 cases.
Conclusions: Non-compliant balloon post-dilation of BVS signiﬁcantly increased the
minimum and mean scaffold diameter. The rate of optimal scaffold expansion
increased by 27%, and the incidence of clinically relevant incomplete scaffold
apposition decreased by 40%.
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Background: Patient reported outcomes (PROs) are increasingly recognized as
important clinical trial endpoints that provide direct information about health
status and help guide clinical and economic decisions. Prior studies have re-
ported quality of life (QoL) decrements attributable to changes in angina status.
The objective of this study was to assess the impact of changes in angina status
following percutaneous coronary intervention (PCI) on QoL in ABSORB II, a
randomized, controlled, multicenter trial that compared the safety and efﬁcacy
of the Absorb Bioresorbable Vascular Scaffold (Abbott Vascular, Santa
Clara, CA) to the XIENCE Everolimus Eluting Stent (Abbott Vascular, Santa
Clara, CA).
Methods: In the ABSORB II trial, we obtained disease-speciﬁc QoL and general
health status information from patients using validated PRO instruments admin-
istered pre-intervention, at 6 months, and 1 year post-discharge. We examined the
timing of changes in angina status in relation to the assessment date of the
EuroQol-5 Dimension Questionnaire (EQ-5D). We compared means and conﬁ-
dence intervals of subjects with changes in angina status within 1 month, 1-3
months, and greater than 3 months prior to assessment. A similar analysis was
conducted for the Seattle Angina Questionnaire (SAQ). Multivariate analysis was
performed to control for observable patient characteristics that might inﬂuence
QoL.
Results: The ABSORB II trial enrolled 501 patients at 46 sites in Europe and New
Zealand and randomized in a 2:1 ratio to Absorb BVS (N¼335) or XIENCE
(N¼166). We will present results of the univariate and multivariate analyses in the
ABSORB II intent-to-treat population.
Conclusions: Research to date indicates that changes in angina status are indepen-
dently associated with reduced QoL. Results from the ABSORB II trial will provide
current evidence of the impact of changes in angina status on QoL following PCI with
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